Addressing mental health problems among persons without stable housing in the context of the COVID-19 pandemic: study protocol for a randomised trial. RESPOND - France.
COVID-19
Doing what matters in times of stress
Economic evaluation
France
Housing instability
Migrant
Problem management plus
Psychological distress
Randomized controlled trial
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
17 11 2023
17 11 2023
Historique:
received:
02
05
2023
accepted:
16
11
2023
medline:
20
11
2023
pubmed:
18
11
2023
entrez:
18
11
2023
Statut:
epublish
Résumé
The COVID-19 pandemic has had an impact on population-wide mental health and well-being. Although people experiencing socioeconomic disadvantage may be especially vulnerable, they experience barriers in accessing mental health care. To overcome these barriers, the World Health Organization (WHO) designed two scalable psychosocial interventions, namely the web-based Doing What Matters in Times of Stress (DWM) and the face-to-face Problem Management Plus (PM+), to help people manage stressful situations. Our study aims to test the effectiveness of a stepped-care program using DWM and PM + among individuals experiencing unstable housing in France - a majority of whom are migrant or have sought asylum. This is a randomised controlled trial to evaluate the effectiveness and cost effectiveness of a stepped-care program using DWM and PM + among persons with psychological distress and experiencing unstable housing, in comparison to enhanced care as usual (eCAU). Participants (N = 210) will be randomised to two parallel groups: eCAU or eCAU plus the stepped-care program. The main study outcomes are symptoms of depression and anxiety measured using the Patient Health Questionnaire Anxiety and Depression Scale (PHQ-ADS). This randomised controlled trial will contribute to a better understanding of effective community-based scalable strategies that can help address the mental health needs of persons experiencing socioeconomic disadvantage, whose needs are high yet who frequently have limited access to mental health care services. this randomised trial has been registered at ClinicalTrials.gov under the number NCT05033210.
Sections du résumé
BACKGROUND
The COVID-19 pandemic has had an impact on population-wide mental health and well-being. Although people experiencing socioeconomic disadvantage may be especially vulnerable, they experience barriers in accessing mental health care. To overcome these barriers, the World Health Organization (WHO) designed two scalable psychosocial interventions, namely the web-based Doing What Matters in Times of Stress (DWM) and the face-to-face Problem Management Plus (PM+), to help people manage stressful situations. Our study aims to test the effectiveness of a stepped-care program using DWM and PM + among individuals experiencing unstable housing in France - a majority of whom are migrant or have sought asylum.
METHODS
This is a randomised controlled trial to evaluate the effectiveness and cost effectiveness of a stepped-care program using DWM and PM + among persons with psychological distress and experiencing unstable housing, in comparison to enhanced care as usual (eCAU). Participants (N = 210) will be randomised to two parallel groups: eCAU or eCAU plus the stepped-care program. The main study outcomes are symptoms of depression and anxiety measured using the Patient Health Questionnaire Anxiety and Depression Scale (PHQ-ADS).
DISCUSSION
This randomised controlled trial will contribute to a better understanding of effective community-based scalable strategies that can help address the mental health needs of persons experiencing socioeconomic disadvantage, whose needs are high yet who frequently have limited access to mental health care services.
TRIAL REGISTRATION
this randomised trial has been registered at ClinicalTrials.gov under the number NCT05033210.
Identifiants
pubmed: 37978577
doi: 10.1186/s12889-023-17238-7
pii: 10.1186/s12889-023-17238-7
pmc: PMC10656934
doi:
Banques de données
ClinicalTrials.gov
['NCT05033210']
Types de publication
Clinical Trial Protocol
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2275Informations de copyright
© 2023. The Author(s).
Références
Psychiatry. 2007 Winter;70(4):283-315; discussion 316-69
pubmed: 18181708
Lancet Glob Health. 2020 Feb;8(2):e254-e263
pubmed: 31981556
Lancet. 2021 Nov 6;398(10312):1700-1712
pubmed: 34634250
PLoS One. 2019 Apr 9;14(4):e0214715
pubmed: 30964883
Psychol Assess. 2018 Mar;30(3):383-395
pubmed: 28493729
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
Psychol Med. 2002 Aug;32(6):959-76
pubmed: 12214795
Public Health Pract (Oxf). 2021 Nov;2:100192
pubmed: 34608460
Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
Glob Ment Health (Camb). 2022 Dec 09;10:e2
pubmed: 36843877
Lancet. 2019 Apr 27;393(10182):1733-1744
pubmed: 30948286
J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57
pubmed: 9881538
PLoS Med. 2022 Mar 17;19(3):e1003949
pubmed: 35298469
Int J Ment Health Syst. 2017 Jun 8;11:40
pubmed: 28603552
JAMA. 2016 Dec 27;316(24):2609-2617
pubmed: 27837602
Pharmacoeconomics. 2020 Apr;38(4):413-425
pubmed: 31912325
World Psychiatry. 2022 Feb;21(1):88-95
pubmed: 35015365
PLoS One. 2020 Dec 28;15(12):e0244630
pubmed: 33370404
Psychosom Med. 2016 Jul-Aug;78(6):716-27
pubmed: 27187854
Front Psychol. 2021 Aug 26;12:710493
pubmed: 34539510
Front Public Health. 2023 Jan 25;11:1100546
pubmed: 36761135
PLoS Med. 2023 Apr 25;20(4):e1004206
pubmed: 37098048
Lancet. 2013 Jul 20;382(9888):183-4
pubmed: 23870520
J Affect Disord. 2019 Mar 1;246:437-443
pubmed: 30599366
PLoS Med. 2017 Aug 15;14(8):e1002371
pubmed: 28809935
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
PLoS One. 2016 Oct 10;11(10):e0161645
pubmed: 27723815
J Affect Disord. 2018 Mar 15;229:314-321
pubmed: 29329065
Digit Health. 2022 Oct 5;8:20552076221129084
pubmed: 36211795